Cargando…

Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort

BACKGROUND: Multidisciplinary attempts to understand the etiology of breast cancer are expanding to increasingly include new potential markers of disease risk. Those efforts may have maximal scientific and practical influence if new findings are placed in context of the well-understood lifestyle and...

Descripción completa

Detalles Bibliográficos
Autores principales: Lacey, James V, Kreimer, Aimee R, Buys, Saundra S, Marcus, Pamela M, Chang, Shih-Chen, Leitzmann, Michael F, Hoover, Robert N, Prorok, Philip C, Berg, Christine D, Hartge, Patricia
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670317/
https://www.ncbi.nlm.nih.gov/pubmed/19292893
http://dx.doi.org/10.1186/1471-2407-9-84
_version_ 1782166310425198592
author Lacey, James V
Kreimer, Aimee R
Buys, Saundra S
Marcus, Pamela M
Chang, Shih-Chen
Leitzmann, Michael F
Hoover, Robert N
Prorok, Philip C
Berg, Christine D
Hartge, Patricia
author_facet Lacey, James V
Kreimer, Aimee R
Buys, Saundra S
Marcus, Pamela M
Chang, Shih-Chen
Leitzmann, Michael F
Hoover, Robert N
Prorok, Philip C
Berg, Christine D
Hartge, Patricia
author_sort Lacey, James V
collection PubMed
description BACKGROUND: Multidisciplinary attempts to understand the etiology of breast cancer are expanding to increasingly include new potential markers of disease risk. Those efforts may have maximal scientific and practical influence if new findings are placed in context of the well-understood lifestyle and reproductive risk factors or existing risk prediction models for breast cancer. We therefore evaluated known risk factors for breast cancer in a cancer screening trial that does not have breast cancer as a study endpoint but is large enough to provide numerous analytic opportunities for breast cancer. METHODS: We evaluated risk factors for breast cancer (N = 2085) among 70,575 women who were randomized in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Using Poisson regression, we calculated adjusted relative risks [RRs, with 95% confidence intervals (CIs)] for lifestyle and reproductive factors during an average of 5 years of follow-up from date of randomization. RESULTS: As expected, increasing age, nulliparity, positive family history of breast cancer, and use of menopausal hormone therapy were positively associated with breast cancer. Later age at menarche (16 years or older vs. < 12: RR = 0.81, 95% CI, 0.65–1.02) or menopause (55 years or older vs. < 45: RR = 1.29, 95% CI, 1.03–1.62) were less strongly associated with breast cancer than was expected. There were weak positive associations between taller height and heavier weight, and only severe obesity [body mass index (BMI; kg/m(2)) 35 or more vs. 18.5–24.9: RR = 1.21, 95% CI, 1.02–1.43] was statistically significantly associated with breast cancer. CONCLUSION: The ongoing PLCO trial offers continued opportunities for new breast cancer investigations, but these analyses suggest that the associations between breast cancer and age at menarche, age at menopause, and obesity might be changing as the underlying demographics of these factors change. CLINICAL TRIALS REGISTRATION: http://www.clinicaltrials.gov, NCT00002540.
format Text
id pubmed-2670317
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26703172009-04-18 Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort Lacey, James V Kreimer, Aimee R Buys, Saundra S Marcus, Pamela M Chang, Shih-Chen Leitzmann, Michael F Hoover, Robert N Prorok, Philip C Berg, Christine D Hartge, Patricia BMC Cancer Research Article BACKGROUND: Multidisciplinary attempts to understand the etiology of breast cancer are expanding to increasingly include new potential markers of disease risk. Those efforts may have maximal scientific and practical influence if new findings are placed in context of the well-understood lifestyle and reproductive risk factors or existing risk prediction models for breast cancer. We therefore evaluated known risk factors for breast cancer in a cancer screening trial that does not have breast cancer as a study endpoint but is large enough to provide numerous analytic opportunities for breast cancer. METHODS: We evaluated risk factors for breast cancer (N = 2085) among 70,575 women who were randomized in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. Using Poisson regression, we calculated adjusted relative risks [RRs, with 95% confidence intervals (CIs)] for lifestyle and reproductive factors during an average of 5 years of follow-up from date of randomization. RESULTS: As expected, increasing age, nulliparity, positive family history of breast cancer, and use of menopausal hormone therapy were positively associated with breast cancer. Later age at menarche (16 years or older vs. < 12: RR = 0.81, 95% CI, 0.65–1.02) or menopause (55 years or older vs. < 45: RR = 1.29, 95% CI, 1.03–1.62) were less strongly associated with breast cancer than was expected. There were weak positive associations between taller height and heavier weight, and only severe obesity [body mass index (BMI; kg/m(2)) 35 or more vs. 18.5–24.9: RR = 1.21, 95% CI, 1.02–1.43] was statistically significantly associated with breast cancer. CONCLUSION: The ongoing PLCO trial offers continued opportunities for new breast cancer investigations, but these analyses suggest that the associations between breast cancer and age at menarche, age at menopause, and obesity might be changing as the underlying demographics of these factors change. CLINICAL TRIALS REGISTRATION: http://www.clinicaltrials.gov, NCT00002540. BioMed Central 2009-03-17 /pmc/articles/PMC2670317/ /pubmed/19292893 http://dx.doi.org/10.1186/1471-2407-9-84 Text en Copyright ©2009 Lacey et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Lacey, James V
Kreimer, Aimee R
Buys, Saundra S
Marcus, Pamela M
Chang, Shih-Chen
Leitzmann, Michael F
Hoover, Robert N
Prorok, Philip C
Berg, Christine D
Hartge, Patricia
Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort
title Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort
title_full Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort
title_fullStr Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort
title_full_unstemmed Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort
title_short Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort
title_sort breast cancer epidemiology according to recognized breast cancer risk factors in the prostate, lung, colorectal and ovarian (plco) cancer screening trial cohort
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670317/
https://www.ncbi.nlm.nih.gov/pubmed/19292893
http://dx.doi.org/10.1186/1471-2407-9-84
work_keys_str_mv AT laceyjamesv breastcancerepidemiologyaccordingtorecognizedbreastcancerriskfactorsintheprostatelungcolorectalandovarianplcocancerscreeningtrialcohort
AT kreimeraimeer breastcancerepidemiologyaccordingtorecognizedbreastcancerriskfactorsintheprostatelungcolorectalandovarianplcocancerscreeningtrialcohort
AT buyssaundras breastcancerepidemiologyaccordingtorecognizedbreastcancerriskfactorsintheprostatelungcolorectalandovarianplcocancerscreeningtrialcohort
AT marcuspamelam breastcancerepidemiologyaccordingtorecognizedbreastcancerriskfactorsintheprostatelungcolorectalandovarianplcocancerscreeningtrialcohort
AT changshihchen breastcancerepidemiologyaccordingtorecognizedbreastcancerriskfactorsintheprostatelungcolorectalandovarianplcocancerscreeningtrialcohort
AT leitzmannmichaelf breastcancerepidemiologyaccordingtorecognizedbreastcancerriskfactorsintheprostatelungcolorectalandovarianplcocancerscreeningtrialcohort
AT hooverrobertn breastcancerepidemiologyaccordingtorecognizedbreastcancerriskfactorsintheprostatelungcolorectalandovarianplcocancerscreeningtrialcohort
AT prorokphilipc breastcancerepidemiologyaccordingtorecognizedbreastcancerriskfactorsintheprostatelungcolorectalandovarianplcocancerscreeningtrialcohort
AT bergchristined breastcancerepidemiologyaccordingtorecognizedbreastcancerriskfactorsintheprostatelungcolorectalandovarianplcocancerscreeningtrialcohort
AT hartgepatricia breastcancerepidemiologyaccordingtorecognizedbreastcancerriskfactorsintheprostatelungcolorectalandovarianplcocancerscreeningtrialcohort